- Home
- LTC vs CGON Comparison
LTC vs CGON Comparison
Compare LTC & CGON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LTC
- CGON
- Stock Information
- Founded
- LTC 1992
- CGON 2010
- Country
- LTC United States
- CGON United States
- Employees
- LTC N/A
- CGON N/A
- Industry
- LTC Real Estate Investment Trusts
- CGON
- Sector
- LTC Real Estate
- CGON
- Exchange
- LTC Nasdaq
- CGON NYSE
- Market Cap
- LTC 1.6B
- CGON 1.3B
- IPO Year
- LTC 1992
- CGON 2024
- Fundamental
- Price
- LTC $35.90
- CGON $23.74
- Analyst Decision
- LTC Buy
- CGON Strong Buy
- Analyst Count
- LTC 4
- CGON 11
- Target Price
- LTC $38.25
- CGON $62.90
- AVG Volume (30 Days)
- LTC 321.9K
- CGON 2.0M
- Earning Date
- LTC 05-05-2025
- CGON 05-20-2025
- Dividend Yield
- LTC 6.34%
- CGON N/A
- EPS Growth
- LTC 0.36
- CGON N/A
- EPS
- LTC 1.93
- CGON N/A
- Revenue
- LTC $202,686,000.00
- CGON $1,139,000.00
- Revenue This Year
- LTC N/A
- CGON N/A
- Revenue Next Year
- LTC $3.56
- CGON $16,237.24
- P/E Ratio
- LTC $18.61
- CGON N/A
- Revenue Growth
- LTC 3.98
- CGON 461.08
- 52 Week Low
- LTC $31.70
- CGON $14.80
- 52 Week High
- LTC $39.89
- CGON $40.47
- Technical
- Relative Strength Index (RSI)
- LTC 55.23
- CGON 49.91
- Support Level
- LTC $34.11
- CGON $21.00
- Resistance Level
- LTC $36.99
- CGON $30.23
- Average True Range (ATR)
- LTC 0.78
- CGON 2.33
- MACD
- LTC 0.05
- CGON 0.06
- Stochastic Oscillator
- LTC 62.15
- CGON 30.94
About LTC LTC Properties Inc.
LTC Properties Inc is a healthcare facility real estate investment trust. The company operates one segment that works to invest in seniors housing and healthcare facilities through mortgage loans, property lease transactions, and other investments. Its real estate investments includes different types of properties such as Independent living communities, Assisted living communities, Memory care communities, Skilled nursing centers and other types of properties.
About CGON CG ONCOLOGY INC
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's lead candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.